Disease mechanisms in Sjögren’s syndrome: What do we know?
Open Access
- 24 January 2022
- journal article
- review article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 95 (3) , e13145
Abstract
Why should we explore and study disease mechanisms? This is particularly important when we are dealing with complex pathogenesis without a direct causal agent, for example, syndromes with multiple organ involvements. Sjögren's syndrome is definitely such an entity. Also, there are a number of reasons for such studies such as disclosing the aetiology, to identify biomarkers for diagnosis and assessment of the disease process and monitor response to treatment, to determine targets for treatment, to define critical items in classification criteria, amongst others. Samples available for the study of disease mechanisms in Sjögren's syndrome have included serum (autoantibodies, cytokines), DNA (gene profiling, GWAS), cells (phenotypes/flow cytometry, proportion of cells/CyTOF), tissue (focal inflammation, germinal centres, mass cytometry), and saliva (proteomics, biochemistry, mucosal immunity). An original explanatory concept for the pathogenesis of Sjögren's syndrome proposed a specific and self‐perpetuating immune‐mediated loss of exocrine tissue as the principal cause of glandular hypofunction. This hypothesis however falls short of accommodating several Sjögren's syndrome‐related phenomena and experimental findings. Today, the emergence of advanced bio‐analytical platforms has further enabled the identification of central pathogenic processes and potential biomarkers. The purpose of this minor review is to highlight a selection of previous but also recent and novel aspects on the disease mechanisms in Sjögren's syndrome.Keywords
This publication has 53 references indexed in Scilit:
- Type 1 Regulatory T Cells and Regulatory B Cells Induced by Tolerogenic Dendritic CellsScandinavian Journal of Immunology, 2013
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2011
- Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survivalArthritis Research & Therapy, 2011
- Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndromeRheumatology, 2009
- Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437–460Arthritis & Rheumatism, 2008
- Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestationsArthritis Research & Therapy, 2008
- Antibodies Raised Against the Second Extracellular Loop of the Human Muscarinic M3 Receptor Mimic Functional Autoantibodies in Sjögren's SyndromeScandinavian Journal of Immunology, 2004
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Serum Antibodies from Patients with Primary Sjögren’s Syndrome and Systemic Lupus Erythematosus Recognize Multiple Epitopes on the La(SS‐B) Autoantigen Resembling Viral Protein SequencesScandinavian Journal of Immunology, 1996
- Expression of HLA-D-locus (DP, DQ, DR)-coded antigens, β2-microglobulin, and the interleukin 2 receptor in Sjögren's syndromeClinical Immunology and Immunopathology, 1987